Loading company…
Souffle Therapeutics develops targeted nucleic acid medicines for genetic muscle and heart disorders.
Souffle Therapeutics develops nucleic acid medicines designed to target disease-related cells, including programs for Facioscapulohumeral Muscular Dystrophy and genetically driven cardiomyopathies. Founded in 2021, the company is based in Watertown, US. In October 2025, it raised USD 200.00 mn in Series A funding from ARCH Venture Partners, Bessemer Venture Partners, Polaris Partners, Leaps by Bayer and Vida Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in